Transgene S.A.
TRGNF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.08 | 0.20 | -0.00 | 0.00 |
| FCF Yield | -17.17% | -25.15% | -2,350.07% | -13.40% |
| EV / EBITDA | -5.58 | -4.73 | 0.03 | -10.26 |
| Quality | ||||
| ROIC | -125.68% | -82.30% | -54.52% | -26.54% |
| Gross Margin | -439.56% | -274.53% | -929.05% | -229.06% |
| Cash Conversion Ratio | 0.69 | 1.55 | 0.62 | 1.64 |
| Growth | ||||
| Revenue 3-Year CAGR | 26.67% | -7.54% | 1.60% | -9.08% |
| Free Cash Flow Growth | 28.85% | -71.34% | 33.07% | -10.26% |
| Safety | ||||
| Net Debt / EBITDA | 0.24 | 0.50 | 0.06 | 0.09 |
| Interest Coverage | -21.21 | 0.00 | -37.19 | -50.70 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 2.01 | 0.00 |
| Cash Conversion Cycle | -33.02 | -14.16 | 444.94 | -85.38 |